Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853015 | 0.93 | KCNJ1 (0.86) | KCNJ1KCNH2 | |
| SCHEMBL18156857 | 0.90 | KCNJ1 (0.70) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16853075 | 0.85 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL18156880 | 0.84 | KCNJ1 (0.88) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16853016 | 0.84 | KCNJ1 (0.78) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL31098422 | 0.84 | KCNJ1 (0.78) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16853017 | 0.84 | KCNJ1 (0.79) | KCNJ1KCNH2 | |
| SCHEMBL18156852 | 0.81 | KCNJ1 (0.74) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL31098389 | 0.80 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL16853059 | 0.80 | KCNJ1 (1.00) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 32/4885ACHE 4869/4885 |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 32/4885ACHE 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.